Cholangiocarcinoma historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 9: | Line 9: | ||
===Discovery=== | ===Discovery=== | ||
*In 1965, Gerald Kaltskin first described adenocarcinoma of hepatic duct at its bifurcation within porta hepatis. It is called Kaltskin tumor.<ref name="pmid14256720">{{cite journal| author=KLATSKIN G| title=ADENOCARCINOMA OF THE HEPATIC DUCT AT ITS BIFURCATION WITHIN THE PORTA HEPATIS. AN UNUSUAL TUMOR WITH DISTINCTIVE CLINICAL AND PATHOLOGICAL FEATURES. | journal=Am J Med | year= 1965 | volume= 38 | issue= | pages= 241-56 | pmid=14256720 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14256720 }} </ref> | |||
*In 1973, Lubana et al reported the first case of primary intrahepatic cholangiocarcinoma with right upper quadrant pain, jaundice, and weight loss.<ref name="pmid26158884">{{cite journal |vauthors=Lubana SS, Singh N, Seligman B, Tuli SS, Heimann DM |title=First Reported Case of Primary Intrahepatic Cholangiocarcinoma with Pure Squamous Cell Histology: A Case Report |journal=Am J Case Rep |volume=16 |issue= |pages=438–44 |year=2015 |pmid=26158884 |pmc=4501643 |doi=10.12659/AJCR.894609 |url=}}</ref> | *In 1973, Lubana et al reported the first case of primary intrahepatic cholangiocarcinoma with right upper quadrant pain, jaundice, and weight loss.<ref name="pmid26158884">{{cite journal |vauthors=Lubana SS, Singh N, Seligman B, Tuli SS, Heimann DM |title=First Reported Case of Primary Intrahepatic Cholangiocarcinoma with Pure Squamous Cell Histology: A Case Report |journal=Am J Case Rep |volume=16 |issue= |pages=438–44 |year=2015 |pmid=26158884 |pmc=4501643 |doi=10.12659/AJCR.894609 |url=}}</ref> | ||
*Following mutations were first implicated in the pathogenesis of cholangiocarcinoma:<ref name="pmid24616382">{{cite journal |vauthors=Silsirivanit A, Sawanyawisuth K, Riggins GJ, Wongkham C |title=Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches |journal=J Hepatobiliary Pancreat Sci |volume=21 |issue=6 |pages=388–96 |year=2014 |pmid=24616382 |pmc=4322866 |doi=10.1002/jhbp.68 |url=}}</ref><ref name="pmid19396965">{{cite journal |vauthors=Alvaro D |title=Serum and bile biomarkers for cholangiocarcinoma |journal=Curr. Opin. Gastroenterol. |volume=25 |issue=3 |pages=279–84 |year=2009 |pmid=19396965 |doi= |url=}}</ref> | *Following mutations were first implicated in the pathogenesis of cholangiocarcinoma:<ref name="pmid24616382">{{cite journal |vauthors=Silsirivanit A, Sawanyawisuth K, Riggins GJ, Wongkham C |title=Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches |journal=J Hepatobiliary Pancreat Sci |volume=21 |issue=6 |pages=388–96 |year=2014 |pmid=24616382 |pmc=4322866 |doi=10.1002/jhbp.68 |url=}}</ref><ref name="pmid19396965">{{cite journal |vauthors=Alvaro D |title=Serum and bile biomarkers for cholangiocarcinoma |journal=Curr. Opin. Gastroenterol. |volume=25 |issue=3 |pages=279–84 |year=2009 |pmid=19396965 |doi= |url=}}</ref> | ||
**Dimensional-differential gel electrophoresis couple with liquid chromatography tandem mass spectrometry (2D-DIGE/LC-MS-MS) | **Dimensional-differential gel electrophoresis couple with liquid chromatography tandem mass spectrometry (2D-DIGE/LC-MS-MS) |
Revision as of 19:31, 6 February 2018
Cholangiocarcinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cholangiocarcinoma historical perspective On the Web |
American Roentgen Ray Society Images of Cholangiocarcinoma historical perspective |
Risk calculators and risk factors for Cholangiocarcinoma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]
Overview
Historical Perspective
Discovery
- In 1965, Gerald Kaltskin first described adenocarcinoma of hepatic duct at its bifurcation within porta hepatis. It is called Kaltskin tumor.[1]
- In 1973, Lubana et al reported the first case of primary intrahepatic cholangiocarcinoma with right upper quadrant pain, jaundice, and weight loss.[2]
- Following mutations were first implicated in the pathogenesis of cholangiocarcinoma:[3][4]
- Dimensional-differential gel electrophoresis couple with liquid chromatography tandem mass spectrometry (2D-DIGE/LC-MS-MS)
- Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS)
- Surface enhanced laser desorption/ionization (SELDI)-TOF-MS
- Capillary electrophoresis (CE)-MS
References
- ↑ KLATSKIN G (1965). "ADENOCARCINOMA OF THE HEPATIC DUCT AT ITS BIFURCATION WITHIN THE PORTA HEPATIS. AN UNUSUAL TUMOR WITH DISTINCTIVE CLINICAL AND PATHOLOGICAL FEATURES". Am J Med. 38: 241–56. PMID 14256720.
- ↑ Lubana SS, Singh N, Seligman B, Tuli SS, Heimann DM (2015). "First Reported Case of Primary Intrahepatic Cholangiocarcinoma with Pure Squamous Cell Histology: A Case Report". Am J Case Rep. 16: 438–44. doi:10.12659/AJCR.894609. PMC 4501643. PMID 26158884.
- ↑ Silsirivanit A, Sawanyawisuth K, Riggins GJ, Wongkham C (2014). "Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches". J Hepatobiliary Pancreat Sci. 21 (6): 388–96. doi:10.1002/jhbp.68. PMC 4322866. PMID 24616382.
- ↑ Alvaro D (2009). "Serum and bile biomarkers for cholangiocarcinoma". Curr. Opin. Gastroenterol. 25 (3): 279–84. PMID 19396965.